NEU neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-182

  1. 1,476 Posts.
    lightbulb Created with Sketch. 373
    personally I think the discussion should be more focused on the company pathway for the next:

    1 month - results
    3 months - digestion of results
    6+ months - decision time regarding the results.

    I feel talk about what $$ everyone is after really doesnt help shape any meaningful thought.

    However, discussions of what Neuren will be doing over the next 6 months will be the main factor that determines any price...for better or worse.

    Like a lot here, ive been invested for 7+ years and for me its all been leading up to PhII value for NNZ - Ive always thought (and continue to now) that Neuren just cant/wont continue further down this path.

    IMO once they have demonstrated the potential of the drug - ie the PhII results for these 4 indications - I feel we will all know the fate of Neuren.

    As usual, good luck to holders !
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.85
Change
-0.110(0.85%)
Mkt cap ! $1.612B
Open High Low Value Volume
$12.82 $12.90 $12.70 $615.3K 48.01K

Buyers (Bids)

No. Vol. Price($)
4 116 $12.84
 

Sellers (Offers)

Price($) Vol. No.
$12.86 413 8
View Market Depth
Last trade - 10.26am 17/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.